Dr. Chandra P. Belani This is Me

Education

 View all 162 references Web References

1. 1. CBCE - The Center for Biomedical Continuing Education - Upcoming Activities

   www.thecbce.com/upcomingActivi - [Cached]

   Published on: 3/28/2008   Last Visited: 3/28/2008

   Chandra P. Belani, MD Penn State College of Medicine, Penn State Milton S. Hershey Medical Center Miriam Beckner Professor of Medicine, Deputy Director, Penn State Cancer Institute
   ...
   Chandra P. Belani
   
   8:30 - 8:35 AM

2. 2. phx.corporate-ir.net

   phx.corporate-ir.net/phoenix.z - [Cached]

   Published on: 3/1/2007   Last Visited: 2/14/2008

   "In my experience, many studies of docetaxel in non-small cell lung cancer are enrolling slowly, primarily due to the increasing use of pemetrexed in the second- and third-line treatment setting, and the increasing use of docetaxel in the front-line setting," said Dr. Chandra Belani, a professor of medicine in the division of hematology/oncology at the University of Pittsburgh School of Medicine, co-director of the Lung and Esophageal Cancer Program at the University of Pittsburgh Cancer Institute and a consultant for Point.

3. 3. cancerfacts.com

   www.cancerfacts.com/Home_News. - [Cached]

   Published on: 8/1/2003   Last Visited: 12/5/2007

   The study, led by Dr. Chandra P. Belani, professor of medicine at the University of Pittsburgh, compared three regimens of weekly paclitaxel plus carboplatin in patients with advanced non-small-cell lung cancer (NSCLC). The results published in the Aug. 1 Journal of Clinical Oncology showed that higher weekly doses of paclitaxel in combination therapy for lung cancer increased the number of adverse side effects, without improving survival.
   
   "Our study demonstrates that both agents can be administered with ease and without substantial toxicity when weekly paclitaxel is combined with full doses of carboplatin administered on day one of each cycle with few side effects," said Dr. Belani in a prepared statement.
   
   "This is a major concern for lung cancer patients with advanced disease given that the primary goal of therapy is to improve survival, reduce symptoms and to improve the patient's quality of life," said Belani, who also is co-director of the Lung Cancer Program at the University of Pittsburgh Cancer Institute (UPCI).
   ...
   Dr. Belani said the results are encouraging and will lead to increasing use of the lower-dose regimen in advanced NSCLC. According to Dr. Belani, a large comparison trial (phase III randomized study) is under way to compare this schedule with the standard three week regimen of paclitaxel and carboplatin.